Form D · Pharmaceuticals

Clovis Oncology, Inc.

Boulder, CO · CIK 0001466301

Offering snapshot reported Nov 27, 2013 · SEC filing

Reported sold
$192M
Indefinite offering
Investors reported
9
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Nov 19, 2013
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Nov 27, 2013Initial$191,962,756No comparison9SEC filing
Jun 2, 2011Initial$20,000,000No comparison18SEC filing
May 18, 2011Amendment$146,300,000$0vs May 19, 201019SEC filing
May 19, 2010Initial$146,300,000No comparison19SEC filing
Jun 25, 2009Initial$146,300,000No comparison19SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
Yes
Sales commissions
$0
Finders' fees
$0
Form D file number
021-207178

Source: Form D, filed Nov 27, 2013. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Andrew R. Allen Executive
Brian G. Atwood Director
M. James Barret Director
James C. Blair Director
Keith Flaherty Director
Ginger L. Graham Director
Steven L. Hoerter Executive
Gillian C. Ivers Read Executive
Paul Klingenstein Director
Patrick J. Mahaffy Director, Executive
Erle T. Mast Executive
Edward J. Mc Kinley Director
Thorlef Spickschen Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
2525 28 Th Street Suite 100
Boulder, CO, 80301